Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Non-smoking subjects~* 6-26 years of age~* Evidence of poor asthma control~* Adherence to ICS \< 50% of doses prescribed over a minimum of 3 months~* Baseline FEV1 \> 60% of predicted~* PC20 AMP \< 60 mg/ml~* Able to perform American Thoracic Society (ATS)-acceptable and reproducible spirometry~Exclusion Criteria:~* Cigarette smoking/use of marijuana~* Pregnancy~* Respiratory infections in past six weeks~* History of acute allergic reaction to asthma/allergy medication~* Total dose requirement of omalizumab more than 375 mg every two weeks~* Inability to withhold required medications before challenge~* Abnormal electrocardiogram (ECG)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).